Press Release: ALK : Report on transactions with ALK-Abell A/S B shares and associated securities by managerial staff
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:
Read full article »
ALK is a Denmark-based pharmaceutical company that researches and develops novel immunotherapies for the treatment of allergies and allergic asthma.
Read more